{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:25:42Z","timestamp":1777566342371,"version":"3.51.4"},"reference-count":19,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T00:00:00Z","timestamp":1351641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The increasing emergence especially of drug-resistant tuberculosis has led to a strong demand for new anti-tuberculosis drugs. Eighteen salicylanilide benzoates were evaluated for their inhibition potential against Mycobacterium tuberculosis, Mycobacterium avium and two strains of Mycobacterium kansasii; minimum inhibitory concentration values ranged from 0.5 to 16 \u03bcmol\/L. The most active esters underwent additional biological assays. Four benzoates inhibited effectively the growth of five multidrug-resistant strains and one extensively drug-resistant strain of M. tuberculosis at low concentrations (0.25\u20132 \u03bcmol\/L) regardless of the resistance patterns. The highest rate of multidrug-resistant mycobacteria inhibition expressed 4-chloro-2-[4-(trifluoromethyl)-phenylcarbamoyl]phenyl benzoate (0.25\u20131 \u03bcmol\/L). Unfortunately, the most potent esters were still considerably cytotoxic, although mostly less than their parent salicylanilides.<\/jats:p>","DOI":"10.3390\/molecules171112812","type":"journal-article","created":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T11:59:41Z","timestamp":1351684781000},"page":"12812-12820","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Antimycobacterial Assessment of Salicylanilide Benzoates including Multidrug-Resistant Tuberculosis Strains"],"prefix":"10.3390","volume":"17","author":[{"given":"Martin","family":"Kr\u00e1tk\u00fd","sequence":"first","affiliation":[{"name":"Department of Inorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, Heyrovsk\u00e9ho 1203, Hradec Kr\u00e1lov\u00e9 50005, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarmila","family":"Vin\u0161ov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, Heyrovsk\u00e9ho 1203, Hradec Kr\u00e1lov\u00e9 50005, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159ina","family":"Stola\u0159\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"Laboratory for Mycobacterial Diagnostics and Tuberculosis, Regional Institute of Public Health in Ostrava, Partyz\u00e1nsk\u00e9 n\u00e1m\u011bst\u00ed 7, Ostrava 70200, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2012,10,31]]},"reference":[{"key":"ref_1","first-page":"998","article-title":"Advances in the Development of Antituberculotics Acting on Multidrug-Resistant Strains","volume":"104","year":"2010","journal-title":"Chem. Listy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jac\/dkr221","article-title":"Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: A study of injectable use and toxicity in practice","volume":"66","author":"Sturdy","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1128\/AAC.05270-11","article-title":"MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212","volume":"56","author":"Poce","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nchembio.794","article-title":"Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane","volume":"8","author":"Grzegorzewicz","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11354","DOI":"10.1073\/pnas.1205735109","article-title":"Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors","volume":"109","author":"Batt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/bmb\/ldq035","article-title":"Nontuberculous mycobacteria: Opportunistic environmental pathogens for predisposed hosts","volume":"96","author":"Cook","year":"2010","journal-title":"Br. Med. Bull."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.2174\/138161211798194521","article-title":"Salicylanilide Ester Prodrugs as Potential Antimicrobial Agents\u2014A Review","volume":"17","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/12010001","article-title":"Salicylanilide Acetates: Synthesis and Antibacterial Evaluation","volume":"12","author":"Vinsova","year":"2007","journal-title":"Molecules"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.bmc.2009.12.055","article-title":"Salicylanilide carbamates: Antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains","volume":"18","author":"Kunc","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1016\/j.ejmech.2010.09.040","article-title":"New amino acid esters ofsalicylanilides active against MDR-TB and other microbes","volume":"45","author":"Buchta","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.bmc.2009.04.008","article-title":"New antituberculotics originated from salicylanilides with promising in vitro activity against atypical mycobacterial strains","volume":"17","author":"Kunc","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/molecules17010492","article-title":"Antimycobacterial Activity of Salicylanilide Benzenesulfonates","volume":"17","author":"Rodriguez","year":"2012","journal-title":"Molecules"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1747-0285.2010.00987.x","article-title":"Inhibition of Mycobacterial Growth by Plumbagin Derivatives","volume":"76","author":"Mathew","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1016\/j.bmc.2010.07.010","article-title":"Identification of novel antitubercular compounds through hybrid virtual screening approach","volume":"18","author":"Muddassar","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1099\/jmm.0.2008\/000786-0","article-title":"Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide","volume":"57","author":"Gu","year":"2008","journal-title":"J. Med. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.tube.2012.06.001","article-title":"Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase","volume":"92","author":"Trejtnar","year":"2012","journal-title":"Tuberculosis"},{"key":"ref_17","first-page":"290628","article-title":"In Vitro Antibacterial and Antifungal Activity of Salicylanilide Benzoates","volume":"2012","author":"Buchta","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ardp.200390004","article-title":"Relationship between the Structure and Antimycobacterial Activity of Substituted Salicylanilides","volume":"336","author":"Waisser","year":"2003","journal-title":"Arch. Pharm. Pharm. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1128\/AAC.43.7.1693","article-title":"Multiple Mechanisms of Action for Inhibitors of Histidine Protein Kinases from Bacterial Two-Component Systems","volume":"43","author":"Hilliard","year":"1999","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/17\/11\/12812\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:53:13Z","timestamp":1760219593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/17\/11\/12812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,31]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"alternative-id":["molecules171112812"],"URL":"https:\/\/doi.org\/10.3390\/molecules171112812","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,31]]}}}